drugset
drugset / Trial / NCT05565729

A Phase I Study of LY3471851 in Healthy Participants

NCT05565729 ↗

Phase 1 Completed 41 enrolled Nektar Therapeutics Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to compare two different formulations (test \& reference) of LY3471851 in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving the study drug that is LY3471851.

Timeline

Start
2022-10-05
Primary completion
2023-02-23
Completion
2023-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezpegaldesleukin Protein / enzyme biologic — Subcutaneous
Background Levocetirizine Unknown — Oral

Indications

No indication recorded.